# Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment

> **NCT07133438** · PHASE4 · RECRUITING · sponsor: **First Affiliated Hospital of Chongqing Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Retinal Vein Occlusion (RVO)

## Interventions

- **DRUG:** Anti-VEGF drug
- **DRUG:** Mecobalamin 5 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07133438
- **Lead sponsor:** First Affiliated Hospital of Chongqing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07133438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07133438, "Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT07133438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*